Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2000
06/06/2000US6071920 Bind to 5ht 1a receptors for treating disorders of the lower urinary tract; cns disorders; anxiolytic agents; antidepressants; hypotensive agents; sleep and eating disorders
06/06/2000US6071919 Stimulate the immunological system and to induce the production of hypercellular bone marrow and extramedullary hematopoiesis; antitumor and -carcinogenic agents; autoimmune diseases; viricides; hepatitis
06/06/2000US6071917 Analgesics; antiinflammatory agents; especially for the treatment of asthma, cerebral traumatic shock and allergic rhinitis; competitive binding at receptors
06/06/2000US6071911 4-amino-1-arylpyridin-2-ones and process for making
06/06/2000US6071909 Phenylbenzimidazole derivatives as ligands for GABA receptors
06/06/2000US6071900 Heterocyclic compounds and their use
06/06/2000US6071899 Azetidinone derivatives for the treatment of atherosclerosis
06/06/2000US6071722 Nucleic acids encoding a G-protein coupled 7TM receptor (AXOR-1)
06/06/2000US6071720 Polynucleotide coding a polypeptide associated with ionic mobility; for the diagnosis, treatment or prevention of nervous system disorders, cardiovascular disorders and cancer; anticarcinogenic agents
06/06/2000US6071523 Oral administering from squeezable container; storage stability, heat resistance; drug delivery
06/06/2000US6071516 Administering normal gamma-globulin
06/06/2000CA2198599C Salts of an anti-migraine indole derivative
06/06/2000CA2015033C Tertiary alkyl functionalized piperazine derivatives
06/06/2000CA1341017C Use of growth hormone releasing factor for improving mental function
06/02/2000WO2000031548A1 Prevention and treatment of amyloid-associated disorders
06/02/2000WO2000031280A2 Use of plus-strand synthesis elements in retroviral vectors
06/02/2000WO2000031265A1 Urotensins ii of mammals and their uses
06/02/2000WO2000031263A2 Gtpase associated proteins
06/02/2000WO2000031253A2 Mutation of the parkin gene, compositions, methods and uses
06/02/2000WO2000031235A2 Nucleotide and protein sequences of nogo genes and methods based thereon
06/02/2000WO2000031133A2 Potassium channel interactors and uses therefor
06/02/2000WO2000031132A1 Novel polypeptide
06/02/2000WO2000031124A2 Peptides that modulate the interaction of b class ephrins and pdz domains
06/02/2000WO2000031123A2 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
06/02/2000WO2000031120A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis
06/02/2000WO2000031083A1 Phospholipid derivatives of non-steroidal anti-inflammatory drugs
06/02/2000WO2000031074A2 Indole derivatives and their use as serotonin receptor ligands
06/02/2000WO2000031065A1 Compounds having cytokine inhibitory activity
06/02/2000WO2000031061A1 2-oxoimidazole derivatives
06/02/2000WO2000031060A1 Scavenger compounds
06/02/2000WO2000031058A1 Novel agarofuan derivatives, their preparation, pharmaceutical composition containing them and their use as medicine
06/02/2000WO2000031039A1 Substituted benzo[de]isoquinoline-1,3-diones
06/02/2000WO2000031038A1 Quinoline derivatives as nk-2 and nk-3 receptor ligands
06/02/2000WO2000031037A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
06/02/2000WO2000031021A1 β-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
06/02/2000WO2000031020A1 Improved gamma amino butyric acid analogs
06/02/2000WO2000030678A1 Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus
06/02/2000WO2000030675A2 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
06/02/2000WO2000030650A1 Desmethylolanzapine compositions and methods
06/02/2000WO2000030649A1 Pharmaceutical compositions containing olanzapine-n-oxide
06/02/2000WO2000030648A1 2-hydroxymethylolanzapine compositions and methods
06/02/2000WO2000030644A1 Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
06/02/2000WO2000030643A1 Novel therapeutic application of nicergoline
06/02/2000WO2000030642A1 Use of nicergoline for treating spasmodism
06/02/2000WO2000030641A1 Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption
06/02/2000WO2000030639A1 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
06/02/2000WO2000030630A1 Combination products of a guanylate cyclase inhibitor and a local anesthetic for pain relief
06/02/2000WO2000030615A1 Method of preparing stable suspensions of insoluble microparticles
06/02/2000WO2000030613A1 New process
06/02/2000WO2000030605A2 Method for producing medicaments from plant extracts, in a solid form of administration
06/02/2000WO2000030446A1 Dosage formulations for acetylcholinesterase inhibitors
06/02/2000WO2000013682A3 4-quinolinemethanol derivatives as purine receptor antagonists.(ii)
06/02/2000WO2000013650A3 Neuroprotection
06/02/2000WO2000012119A3 PHARMACEUTICAL COMPOSITIONS COMPRISING FACTOR XIIIa
06/02/2000WO2000009105A3 Small molecule carbamates or ureas for vision and memory disorders
06/02/2000WO2000006203A9 Dna cytokine vaccines and use of same for protective immunity against multiple sclerosis
06/02/2000WO1999066075A3 Diagnostic method based on quantification of extramitochondrial dna
06/02/2000CA2352617A1 Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus
06/02/2000CA2352611A1 2-hydroxymethylolanzapine compositions and methods
06/02/2000CA2352606A1 Urotensins ii of mammals and their uses
06/02/2000CA2352526A1 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
06/02/2000CA2352347A1 Novel polypeptide
06/02/2000CA2352144A1 Scavenger compounds
06/02/2000CA2351893A1 Peptides that modulate the interaction of b class ephrins and pdz domains
06/02/2000CA2351865A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
06/02/2000CA2351719A1 Pharmaceutical compositions containing olanzapine-n-oxide
06/02/2000CA2351718A1 Desmethylolanzapine compositions and methods
06/02/2000CA2351692A1 Inhibitors of production and/or secretion of amyloid-.beta. protein
06/02/2000CA2351630A1 Vector
06/02/2000CA2351567A1 Mutation of the parkin gene, compositions, methods and uses
06/02/2000CA2351526A1 Indole derivatives and their use as serotonin receptor ligands
06/02/2000CA2351365A1 Potassium channel interactors and uses therefor
06/02/2000CA2351361A1 Gtpase associated proteins
06/02/2000CA2351354A1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis
06/02/2000CA2351348A1 Substituted benzo[de]isoquinoline-1,3-diones
06/02/2000CA2351347A1 Dosage formulations for acetylcholinesterase inhibitors
06/02/2000CA2350969A1 Compounds having cytokine inhibitory activity
06/02/2000CA2350395A1 Nucleotide and protein sequences of nogo genes and methods based thereon
06/02/2000CA2349290A1 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
06/02/2000CA2349229A1 Prevention and treatment of amyloid-associated disorders
05/2000
05/31/2000EP1004586A2 Method for producing 2-methylspiro(1,3-Oxathiolane-5,3')quinuclidine
05/31/2000EP1004582A2 Pyridazino quinoline compounds
05/31/2000EP1004578A2 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
05/31/2000EP1004314A1 T.d. Polio booster vaccine for a primovaccinated or sensibilisated population
05/31/2000EP1004312A1 Method for treating multiple sclerosis
05/31/2000EP1003859A1 Use of transcription factor brn-3a
05/31/2000EP1003856A1 Apaf-1, the ced-4 human homolog, an activator of caspase-3
05/31/2000EP1003784A1 Novel peptides and polypeptides useful for regenerating the nervous system
05/31/2000EP1003770A1 Secreted proteins and polynucleotides encoding them
05/31/2000EP1003763A1 83 human secreted proteins
05/31/2000EP1003752A1 3-substituted 3,4,5,7-tetrahydro-pyrrolo3',4':4,5 thieno2,3-dpyrimidine derivatives, their preparation and use as 5ht antagonists
05/31/2000EP1003751A1 Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
05/31/2000EP1003749A1 8-SUBSTITUTED-9H-1,3-DIOXOLO/4,5-h/2,3/BENZODIAZEPINE DERIVATES, AS AMPA/KAINATERECEPTOR INHIBITORS
05/31/2000EP1003746A1 Purine inhibitor of protein kinases, g proteins and polymerases
05/31/2000EP1003744A1 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS
05/31/2000EP1003740A2 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagoists
05/31/2000EP1003739A2 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
05/31/2000EP1003738A1 Bicyclic compounds as ligands for 5-ht1 receptors
05/31/2000EP1003737A1 Phenyl urea and phenyl thiourea derivatives as hfgan72 antagonists
05/31/2000EP1003728A1 2- 3- 4-(2-t-butyl-6- trifluoromethylpyridin-4-yl) piperazin-1-yl] propylmercapto pyrimidin-4-ol-fumarate
1 ... 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 ... 1833